Fiche société
Guangdong Ruishun Biotech Co., Ltd
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| RJMty19 (CD19-CAR-DNT cells)This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus erythematosus (SLE) subjects. | Lupus | Phase 1 | Immunomodulation | China | À vérifier |
| RJMty19 (CD19-CAR-DNT cells)This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus erythematosus (SLE) subjects. | Lupus | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| RJMty19 (CD19-CAR-DNT cells) | Lupus | Phase 1 | NCT06340490 | A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) | NOT_YET_RECRUITING |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| RJMty19 (CD19-CAR-DNT cells) | CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study. | EClinicalMedicine |